Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study

[1]  A. Gottlieb,et al.  Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus‐Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis , 2018, Arthritis & rheumatology.

[2]  B. Shea,et al.  Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016 , 2017, The Journal of Rheumatology.

[3]  A. Gottlieb,et al.  Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study , 2017, Rheumatology.

[4]  P. Geusens,et al.  Secukinumab for Long‐Term Treatment of Psoriatic Arthritis: A Two‐Year Followup From a Phase III, Randomized, Double‐Blind Placebo‐Controlled Study , 2017, Arthritis care & research.

[5]  L. Egede,et al.  The impact of arthritis and joint pain on individual healthcare expenditures: findings from the Medical Expenditure Panel Survey (MEPS), 2011 , 2017, Arthritis Research & Therapy.

[6]  V. Strand,et al.  Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1) , 2016, Annals of the rheumatic diseases.

[7]  A. Gottlieb,et al.  Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis , 2016, Arthritis & rheumatology.

[8]  A. Kavanaugh,et al.  Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey , 2016, Rheumatology and Therapy.

[9]  M. Lebwohl,et al.  US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey , 2015, American Journal of Clinical Dermatology.

[10]  D. M. van der Heijde,et al.  Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. , 2015, The New England journal of medicine.

[11]  A. Gottlieb,et al.  Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.

[12]  G. Guyatt,et al.  Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop , 2015, The Journal of Rheumatology.

[13]  G. Haugeberg,et al.  A Comparison of Disease Burden in Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis , 2015, PloS one.

[14]  B. Elewski,et al.  Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.

[15]  M. D. de Wit,et al.  A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative , 2014, Annals of the rheumatic diseases.

[16]  J. Gómez-Reino,et al.  Health-related quality of life in psoriatic arthritis patients in Spain. , 2014, Reumatologia clinica.

[17]  L. P. L. Schetino,et al.  Increased levels of IL-17A in patients with fibromyalgia. , 2013, Clinical and experimental rheumatology.

[18]  W. Tillett,et al.  Work disability in psoriatic arthritis: a systematic review. , 2012, Rheumatology.

[19]  Gila Moalem-Taylor,et al.  Interleukin-17 contributes to neuroinflammation and neuropathic pain following peripheral nerve injury in mice. , 2011, The journal of pain : official journal of the American Pain Society.

[20]  A. Mendelsohn,et al.  The burden of psoriatic arthritis: a literature review from a global health systems perspective. , 2010, P & T : a peer-reviewed journal for formulary management.

[21]  L. Coates,et al.  Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment , 2009, Annals of the rheumatic diseases.

[22]  A. Gottlieb,et al.  Treatment recommendations for psoriatic arthritis , 2008, Annals of the rheumatic diseases.

[23]  D. Gladman.  Psoriatic arthritis , 2009, Dermatologic therapy.

[24]  E. Choy,et al.  Fatigue in rheumatoid arthritis reflects pain, not disease activity. , 2006, Rheumatology.

[25]  D. Gladman,et al.  Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. , 2001, Arthritis and rheumatism.

[26]  W. Eyler,et al.  PSORIATIC ARTHRITIS. , 1965, Henry Ford Hospital medical bulletin.